DD231350A5 - Verfahren zur herstellung von 6-phenyl-4,5-dihydro-3(2h)-pyridazinon-verbindungen und ihren salzen - Google Patents

Verfahren zur herstellung von 6-phenyl-4,5-dihydro-3(2h)-pyridazinon-verbindungen und ihren salzen Download PDF

Info

Publication number
DD231350A5
DD231350A5 DD85272500A DD27250085A DD231350A5 DD 231350 A5 DD231350 A5 DD 231350A5 DD 85272500 A DD85272500 A DD 85272500A DD 27250085 A DD27250085 A DD 27250085A DD 231350 A5 DD231350 A5 DD 231350A5
Authority
DD
German Democratic Republic
Prior art keywords
general formula
compound
group
compounds
dihydro
Prior art date
Application number
DD85272500A
Other languages
German (de)
English (en)
Inventor
Robert A Slater
Original Assignee
�����@�����@���@������@������������@�������k��
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by �����@�����@���@������@������������@�������k�� filed Critical �����@�����@���@������@������������@�������k��
Publication of DD231350A5 publication Critical patent/DD231350A5/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/22Nitrogen and oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/28Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to cyano groups, e.g. cyanoguanidines, dicyandiamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/04Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Hydrogenated Pyridines (AREA)
DD85272500A 1984-01-13 1985-01-10 Verfahren zur herstellung von 6-phenyl-4,5-dihydro-3(2h)-pyridazinon-verbindungen und ihren salzen DD231350A5 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB848400863A GB8400863D0 (en) 1984-01-13 1984-01-13 Chemical compounds

Publications (1)

Publication Number Publication Date
DD231350A5 true DD231350A5 (de) 1985-12-24

Family

ID=10554924

Family Applications (1)

Application Number Title Priority Date Filing Date
DD85272500A DD231350A5 (de) 1984-01-13 1985-01-10 Verfahren zur herstellung von 6-phenyl-4,5-dihydro-3(2h)-pyridazinon-verbindungen und ihren salzen

Country Status (31)

Country Link
US (1) US4654342A (h)
EP (1) EP0150937B1 (h)
JP (3) JPS60158181A (h)
KR (1) KR920006781B1 (h)
CN (1) CN85101722A (h)
AT (1) ATE37179T1 (h)
AU (1) AU572252B2 (h)
CA (2) CA1251209A (h)
CS (1) CS248731B2 (h)
DD (1) DD231350A5 (h)
DE (1) DE3564941D1 (h)
DK (1) DK162519C (h)
ES (3) ES8607949A1 (h)
FI (1) FI850140A7 (h)
GB (1) GB8400863D0 (h)
GR (1) GR850068B (h)
HU (1) HU193591B (h)
IE (1) IE57969B1 (h)
IL (1) IL74031A (h)
JO (1) JO1351B1 (h)
MY (1) MY100124A (h)
NO (1) NO850129L (h)
NZ (1) NZ210816A (h)
PH (1) PH22136A (h)
PL (1) PL147123B1 (h)
PT (1) PT79819B (h)
RO (1) RO92607A (h)
SU (1) SU1396963A3 (h)
WO (1) WO1985003076A1 (h)
ZA (1) ZA85251B (h)
ZW (1) ZW385A1 (h)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1251448A (en) * 1985-03-27 1989-03-21 William J. Coates Pyridazinone derivatives
AU581324B2 (en) * 1985-07-05 1989-02-16 Smith Kline & French Laboratories Limited Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones
GB8603780D0 (en) * 1986-02-15 1986-03-19 Smith Kline French Lab Chemical compounds
GB8722776D0 (en) * 1987-09-28 1987-11-04 Smith Kline French Lab Chemical compounds
US5011837A (en) * 1988-08-09 1991-04-30 E. R. Squibb & Sons, Inc. Aryl cyanoguanidines: potassium channel activators and method of making same
NZ229828A (en) * 1988-08-09 1992-03-26 Squibb & Sons Inc Aryl cyanoguanidine derivatives and pharmaceutical compositions
DE60213958T2 (de) * 2001-02-27 2007-08-30 Migenix Corp., San Diego Aryl-n-cyanoguanidine derivate und deren verwendung
US7141572B2 (en) * 2001-11-05 2006-11-28 Merck Patent Gesellschaft Hydrazono-malonitriles
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
EP1956906A4 (en) 2005-11-09 2009-12-30 Combinatorx Inc METHODS, COMPOSITIONS AND KITS FOR THE TREATMENT OF PATHOLOGIES
WO2007054514A2 (en) * 2005-11-14 2007-05-18 Boehringer Ingelheim Vetmedica Gmbh Use of pde iii inhibitors or calcium sensitizers for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2998314B1 (en) 2007-06-04 2020-01-22 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2328910B1 (en) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
MX2011005444A (es) 2008-11-25 2011-06-09 Boehringer Ingelheim Vetmed Inhibidores de la fosfodiesterasa tipo iii (pde iii) o agentes sensibilizantes a iones de ca(2+) para el tratamiento de la cardiomiopatia hipertrofica.
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3366698A1 (en) 2011-03-01 2018-08-29 Synergy Pharmaceuticals Inc. Guanylate cyclase c agonists
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
EP2825159B1 (en) 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
CA2902348C (en) 2013-02-25 2021-11-30 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
PL3021832T3 (pl) 2013-07-19 2021-08-23 Boehringer Ingelheim Vetmedica Gmbh Konserwowana ciekła wodna kompozycja farmaceutyczna zawierająca eteryfikowane pochodne cyklodekstryny
KR20220147691A (ko) 2013-08-09 2022-11-03 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
DK3106150T3 (da) 2013-12-04 2021-11-01 Boehringer Ingelheim Vetmedica Gmbh Forbedrede farmaceutiske sammensætninger af pimobendan
CN104987310A (zh) * 2015-06-03 2015-10-21 青岛农业大学 左西孟旦的合成工艺
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
CN110117257B (zh) * 2018-02-05 2022-12-06 安徽省新星药物开发有限责任公司 一种含胍基的p2y12受体拮抗剂、制备方法及其用途
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3822260A (en) * 1970-10-09 1974-07-02 American Cyanamid Co 6-(cyanophenyl)-4,5-dihydro-3(2h)-pyridazinones
BE791539A (fr) * 1971-11-19 1973-05-17 Basf Ag Dihydropyridazones, leur preparation et leurs utilisations therapeutiques
DE3063196D1 (en) * 1979-12-05 1983-06-16 Morishita Pharma Derivatives of 2-substituted-6-phenyl-3(2h)pyridazinone, their production and pharmaceutical compositions containing them
ATE13294T1 (de) * 1981-03-04 1985-06-15 Ciba Geigy Ag Pyridazinone, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen und deren verwendung.
JPS58113180A (ja) * 1981-12-28 1983-07-05 Mitsui Toatsu Chem Inc ピリダジノン誘導体
DE3204375C2 (de) * 1982-02-09 1983-12-01 J. Rettenmaier & Söhne GmbH + Co, 7091 Holzmühle Verfahren zur Herabsetzung der Saugfähigkeit von Holz
JPS58140076A (ja) * 1982-02-09 1983-08-19 Mitsubishi Chem Ind Ltd ピリダジノン誘導体又はその塩類
DE3302021A1 (de) * 1983-01-22 1984-07-26 Basf Ag, 6700 Ludwigshafen 6-aryl-4,5-dihydro-3(2h)-pyridazinone, ihre herstellung und verwendung
AU581324B2 (en) * 1985-07-05 1989-02-16 Smith Kline & French Laboratories Limited Substituted 6-phenyl-4,5-dihydro pyradazin-3-ones

Also Published As

Publication number Publication date
DK162519C (da) 1992-03-30
ES8703846A1 (es) 1987-03-01
EP0150937A3 (en) 1985-08-21
AU572252B2 (en) 1988-05-05
FI850140L (fi) 1985-07-14
ES549629A0 (es) 1987-03-01
DK9185D0 (da) 1985-01-08
DK9185A (da) 1985-07-14
SU1396963A3 (ru) 1988-05-15
RO92607A (ro) 1987-11-30
PH22136A (en) 1988-06-01
ES554965A0 (es) 1987-07-01
PT79819B (en) 1987-01-07
GB8400863D0 (en) 1984-02-15
ZW385A1 (en) 1985-08-07
ES8706645A1 (es) 1987-07-01
EP0150937A2 (en) 1985-08-07
MY100124A (en) 1989-12-18
NZ210816A (en) 1987-06-30
PT79819A (en) 1985-02-01
PL251516A1 (en) 1985-12-17
JPS60158181A (ja) 1985-08-19
JPS63313775A (ja) 1988-12-21
JO1351B1 (en) 1986-11-30
KR920006781B1 (ko) 1992-08-17
DK162519B (da) 1991-11-11
ES539446A0 (es) 1986-06-01
CA1260471C (h) 1989-09-26
IL74031A0 (en) 1985-04-30
HU193591B (en) 1987-11-30
IE850069L (en) 1985-07-13
PL147123B1 (en) 1989-04-29
WO1985003076A1 (en) 1985-07-18
ZA85251B (en) 1986-08-27
JPS63313776A (ja) 1988-12-21
ES8607949A1 (es) 1986-06-01
ATE37179T1 (de) 1988-09-15
CA1251209A (en) 1989-03-14
EP0150937B1 (en) 1988-09-14
DE3564941D1 (en) 1988-10-20
AU3761185A (en) 1985-07-18
FI850140A0 (fi) 1985-01-11
IE57969B1 (en) 1993-06-02
IL74031A (en) 1988-07-31
CN85101722A (zh) 1987-01-31
NO850129L (no) 1985-07-15
CA1260471A (en) 1989-09-26
US4654342A (en) 1987-03-31
FI850140A7 (fi) 1985-07-14
HUT37128A (en) 1985-11-28
CS248731B2 (en) 1987-02-12
GR850068B (h) 1985-05-03
KR850005417A (ko) 1985-08-26

Similar Documents

Publication Publication Date Title
DD231350A5 (de) Verfahren zur herstellung von 6-phenyl-4,5-dihydro-3(2h)-pyridazinon-verbindungen und ihren salzen
DE69132961T2 (de) Styrylsubstituierte heteroarylverbindungen, welche egf-rezeptor-tyrosinkinase inhibieren
EP0012361B1 (de) Amino-pyrimidin-carbanilide, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel
DD211555A5 (de) Verfahren zur herstellung neuer 4-amino-6,7-dimethoxychinolin-derivate
EP0000113B1 (de) Dihydropyridazone, ihre Herstellung und sie enthaltende Arzneimittel sowie Dihydropyridazone zur Verwendung für therapeutische Behandlung
DE2934747A1 (de) Tetrazolylalkoxycarbostyrilderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten
EP0117403B1 (de) 6-(Acylaminoaryl)-3(2H)-pyridazinonderivate, ihre Herstellung und Verwendung
DE69610036T2 (de) Pyridazinone-Derivate und Verfahren zur deren Herstellung
DE2236987A1 (de) Pyrazolo eckige klammer auf 1,5a eckige klammer zu -pyrimidine und verfahren zu ihrer herstellung
DE69115526T2 (de) 2,4-Pyrimidindionderivate und diese enthaltende Arzneimittel
DE68925270T2 (de) Pyrrolo[3,2-e]pyrazolo[1,5-a]pyrimidinderivate und diese enthaltende Arzneimittel
DE69127976T2 (de) Tropolonderivate und pharmazeutische zubereitungen davon zur vorbeugung und behandlung von ischämischen krankheiten
DE69512816T2 (de) Oxopyridylchinoxalin Derivate
CH619462A5 (en) Process for the preparation of novel piperazinylpyrazines
EP0021338B1 (de) Neue Chinazolinderivate und pharmazeutische Präparate
DE69019294T4 (de) Triazolyl-Hydrazidderivate und Verfahren zu ihrer Herstellung.
AT392469B (de) Verfahren zur herstellung von neuen chinolinderivaten
AT395423B (de) Neue 2-carbonyl substituierte n,n'-di(trimethoxybenzoyl)piperazine, verfahren zu deren herstellung und sie enthaltende therapeutische zusammensetzungen
EP0071102A1 (de) Neue Benztriazole, ihre Herstellung und ihre Verwendung als Arzneimittel
DE2322561A1 (de) Trisubstituierte imidazole
DE2322350A1 (de) 1,8-naphthyridin-2(1h)-on-derivate und verfahren zu ihrer herstellung
DE2708187A1 (de) Neue pyrido-pyridazin-one
EP0089528A1 (de) 6-Aryl-4,5-dihydro-3(2H)-pyridazinone,ihre Herstellung und Verwendung
DE3324727C2 (h)
DE69523640T2 (de) Substituierte 6-r-1,3,4-thiadiazin-2-amine, deren verwendung als anaesthetische, cardiovaskulare und hypometabolische mittel, und eine sie enthaltende pharmazeutische zubereitung

Legal Events

Date Code Title Description
PJ Ceased due to non-payment of renewal fee (addendum to changes before extension act)